Tag: Chad Cowan
-
Science & Tech
‘Any patient with any disease’
Developed through Harvard’s Blavatnik Biomedical Accelerator, an innovative immune-silent stem cell technology could lead to novel cell therapies to treat “any patient with any disease.”

-
Health
A pill to shed fat?
Harvard Stem Cell Institute researchers have taken what they describe as “the first step toward a pill that can replace the treadmill” for the control of obesity.

-
Health
A promising strategy against HIV
Harvard Stem Cell Institute researchers at Massachusetts General and Boston Children’s hospitals for the first time have used a relatively new gene-editing technique to create what could prove to be an effective technique for blocking HIV from invading and destroying patients’ immune systems.

-
Health
Obesity? Diabetes? We’ve been set up
The twin epidemics of obesity and its cousin, diabetes, have been the target of numerous studies at Harvard and its affiliated hospitals and institutions. Harvard researchers have produced a dizzying array of findings on the often related problems.

-
Health
Efficiency of producing iPS cells markedly improved
Some of the most challenging obstacles limiting the reprogramming of mature human cells into stem cells may not seem quite as daunting in the near future. Two independent research groups, one lead by Harvard Stem Cell Institute Principal Faculty member Konrad Hochedlinger, and another at the Whitehead Institute, are describing new tools that provide invaluable…
-
Health
Daley and colleagues create 20 disease-specific stem cell lines
Harvard Stem Cell Institute (HSCI) researcher George Q. Daley, associate director of the Stem Cell Program at Children’s Hospital Boston, has with HSCI colleagues Chad Cowan and Konrad Hochedlinger of Massachusetts General Hospital (MGH) produced a robust new collection of disease-specific stem cell lines, all of which were developed using the new induced pluripotent stem…
-
Health
GlaxoSmithKline and Harvard Stem Cell Institute announce major collaboration agreement
GlaxoSmithKline (GSK) and the Harvard Stem Cell Institute (HSCI) today announced that they have entered into a five-year, $25 million-plus collaborative agreement to build a unique alliance in stem cell science to hasten the development of treatments and cures for a range of diseases. GSK’s investment, one of the largest by a pharmaceutical company in…
-
Health
Reprogrammed adult skin cells treat Parkinson’s disease in animal model
Researchers at the Whitehead Institute and Harvard Stem Cell Institute(HSCI) have reported successfully reducing symptoms in a Parkinson’s disease rat model by using dopamine producing neurons derived from reprogrammed adult skin cells(iPS). The work was reported in a study published in the online Early Edition of Proceedings of the National Academy of Science. “This is the…
-
Campus & Community
Adult cells transformed into stem cells
Harvard researchers fused adult skin cells with embryonic stem cells in such a way that the genes of the embryonic cells reset the genetic clock of the adult cells, turning them back to their embryonic form. Such adult-cum-embryo cells, taken from people with juvenile diabetes, Parkinson’s, Alzheimer’s, and other genetic diseases, could reveal how such…
